Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2025)

Crinetics Pharmaceuticals has reported Research & Development over the past 9 years, most recently at $85.1 million for Q4 2025.

  • For Q4 2025, Research & Development rose 27.77% year-over-year to $85.1 million; the TTM value through Dec 2025 reached $332.1 million, up 38.27%, while the annual FY2025 figure was $332.1 million, 38.27% up from the prior year.
  • Research & Development for Q4 2025 was $85.1 million at Crinetics Pharmaceuticals, down from $90.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $90.5 million in Q3 2025 and troughed at $17.6 million in Q1 2021.
  • A 5-year average of $47.8 million and a median of $42.2 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 62.5% in 2021 and later grew 23.17% in 2023.
  • Year by year, Research & Development stood at $24.6 million in 2021, then soared by 50.35% to $37.0 million in 2022, then rose by 23.22% to $45.6 million in 2023, then surged by 46.04% to $66.6 million in 2024, then increased by 27.77% to $85.1 million in 2025.
  • Business Quant data shows Research & Development for CRNX at $85.1 million in Q4 2025, $90.5 million in Q3 2025, and $80.3 million in Q2 2025.